Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma.
Markus W LöfflerChristopher MohrLeon BichmannLena Katharina FreudenmannMathias WalzerChristopher M SchroederNico TrautweinFranz J HilkeRaphael S ZinserLena MühlenbruchDaniel J KowalewskiHeiko SchusterMarc SturmJakob MatthesOlaf RiessStefan CzemmelSven NahnsenIngmar KönigsrainerKarolin ThielSilvio NadalinStefan BeckertHans BösmüllerFalko FendAna VelicBoris MačekSebastian P HaenLuigi BuonaguroOliver KohlbacherStefan StevanovićAlfred Königsrainernull nullHans-Georg RammenseePublished in: Genome medicine (2019)
This study suggests that exome-derived mutated HLA ligands appear to be rarely presented in HCCs, inter alia resulting from a low mutational burden as compared to other malignancies such as malignant melanoma. Our results therefore demand widening the target scope for personalized immunotherapy beyond this limited range of mutated neoepitopes, particularly for malignancies with similar or lower mutational burden.